Undisclosed IL-12/IL-15 viral therapeutic / Candel Therap - LARVOL DELTA

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) - "Third Quarter 2024 & Recent Highlights:...enLIGHTEN Discovery Platform: Presented poster titled 'A first-in-class multimodal immunotherapy for enhanced immune activation in the tumor microenvironment as a novel therapeutic strategy for solid tumors' at IOVC. The presentation focused on the latest asset from the enLIGHTEN Discovery Platform, a multimodal viral therapeutic candidate encoding IL-12 and IL-15. Data showed the ability of the asset to induce expansion and activation of natural killer and CD8+ T cell populations, resulting in significant tumor growth inhibition and regression in two different models."

Preclinical • Solid Tumor